SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes

被引：0
|
作者：
Gajos, Grzegorz [1 ,2 ]
机构：
[1] Jagiellonian Univ Med Coll, Inst Cardiol, Dept Coronary Artery Dis & Heart Failure, Krakow, Poland
[2] St John Paul II Hosp, Krakow, Poland
来源：
CARDIOLOGY JOURNAL | 2024年 / 31卷 / 05期
关键词：
D O I：
10.5603/cj.102158
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：782 / 783
页数：2
相关论文
共 50 条
  • [1] Semaglutide and cardiovascular outcomes in obesity without diabetes
    Basolo, A.
    Fierabracci, P.
    Salvetti, G.
    Santini, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (05) : 1047 - 1049
  • [2] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
    Lincoff, A. Michael
    Brown-Frandsen, Kirstine
    Colhoun, Helen M.
    Deanfield, John
    Emerson, Scott S.
    Esbjerg, Sille
    Hardt-Lindberg, Soren
    Hovingh, G. Kees
    Kahn, Steven E.
    Kushner, Robert F.
    Lingvay, Ildiko
    Oral, Tugce K.
    Michelsen, Marie M.
    Plutzky, Jorge
    Tornoe, Christoffer W.
    Ryan, Donna H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (24): : 2221 - 2232
  • [3] Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes
    A. Basolo
    P. Fierabracci
    G. Salvetti
    F. Santini
    Journal of Endocrinological Investigation, 2024, 47 : 1047 - 1049
  • [4] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease
    Lincoff, A. Michael
    Ryan, Donna H.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (02) : 93 - 94
  • [5] SEMAGLUTIDE, INFLAMMATORY MARKERS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH OVERWEIGHT OR OBESITY IN THE SELECT TRIAL
    Plutzky, Jorge
    Bogdanski, Pawel
    Dagdelen, Selcuk
    Deanfield, John
    Emerson, Scott
    Hovingh, G.
    Kahn, Steven
    Larsen, Signe
    Latkovskis, Gustavs
    Lehrke, Michael
    Hardt-Lindberg, Soren
    Lingvay, Ildiko
    Nicholls, Stephen
    Oral, Tugce
    Terns, Paula Perez
    Rasmussen, Soren
    Ridker, Paul
    Ryan, Donna
    Lincoff, A. Michael
    ATHEROSCLEROSIS, 2024, 395
  • [6] Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
    Colhoun, Helen M.
    Lingvay, Ildiko
    Brown, Paul M.
    Deanfield, John
    Brown-Frandsen, Kirstine
    Kahn, Steven E.
    Plutzky, Jorge
    Node, Koichi
    Parkhomenko, Alexander
    Ryden, Lars
    Wilding, John P. H.
    Mann, Johannes F. E.
    Tuttle, Katherine R.
    Idorn, Thomas
    Rathor, Naveen
    Lincoff, A. Michael
    NATURE MEDICINE, 2024, 30 (07) : 2058 - 2066
  • [7] Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) Outcomes by Sex
    Verma, Subodh
    Colhoun, Helen M.
    Dicker, Dror
    Hovingh, G. Kees
    Kahn, Steven E.
    Kautzky-Willer, Alexandra
    Lingvay, Ildiko
    Plutzky, Jorge
    Rasmussen, Soren
    Rathor, Naveen
    Tetens, Soren
    Lincoff, A. Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (17) : 1678 - 1682
  • [8] Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes
    Mcewan, Phil
    Bog, Martin
    Faurby, Mads
    Foos, Volker
    Lingvay, Ildiko
    Luebker, Christopher
    Miller, Ryan
    Toliver, Joshua C.
    Yeates, Florian
    Lincoff, A. Michael
    JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 268 - 278
  • [9] Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial
    Colhoun, Helen M.
    Lingvay, Ildiko
    Brown, Paul M.
    Deanfield, John
    Brown-Frandsen, Kirstine
    Kahn, Steven E.
    Plutzky, Jorge
    Node, Koichi
    Parkhomenko, Alexander
    Ryden, Lars
    Wilding, John P. H.
    Mann, Johannes F. E.
    Tuttle, Katherine R.
    Idorn, Thomas
    Rathor, Naveen
    Lincoff, A. Michael
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [10] Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial
    Colhoun, Helen M.
    Lingvay, Ildiko
    Brown, Paul M.
    Deanfield, John
    Brown-Frandsen, Kirstine
    Kahn, Steven E.
    Plutzky, Jorge
    Node, Koichi
    Parkhomenko, Alexander
    Ryden, Lars
    Wilding, John P. H.
    Mann, Johannes F. E.
    Tuttle, Katherine R.
    Idorn, Thomas
    Rathor, Naveen
    Lincoff, A. Michael
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1128 - I1130
12345